Sponsor: 
GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Meningococcal B vaccines

Registered for use in people aged ≥2 months.

MenB-MC — recombinant multicomponent meningococcal serogroup B vaccine

Each 0.5 mL monodose pre-filled syringe contains:

  • 50 µg Neisseria meningitidis serogroup B Neisseria heparin binding antigen fusion protein
  • 50 µg Neisseria meningitidis serogroup B Neisseria adhesion A protein
  • 50 µg Neisseria meningitidis serogroup B factor H binding protein fusion protein
  • 25 µg outer membrane vesicles from Neisseria meningitidis serogroup B strain NZ98/254 (measured as amount of total protein containing the PorA P1.4)

Adsorbed onto 0.5 mg aluminium hydroxide.

For full details, refer to the product information and consumer medicine information sheets for Bexsero vaccine available on the TGA website.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018